• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

FDA approves historic alopecia treatment

By
Madison Muller
Madison Muller
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Madison Muller
Madison Muller
and
Bloomberg
Bloomberg
Down Arrow Button Icon
June 14, 2022, 1:25 PM ET
BSIP—Universal Images Group/Getty Images

The Food and Drug Administration on Monday approved the first systemic treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects more than 300,000 people in the U.S. Each year.

The drug is sold by Eli Lilly & Co. And Incyte Corp. Under the brand name Olumiant and comes in the form of oral tablets taken once daily. It’s approved for adult patients with severe alopecia. In two big trials, about 40% of people with severe alopecia achieved significant hair growth after 36 weeks, according to the FDA.

Today, we approved oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. Each year. Https://t.co/POFOIvvul8pic.twitter.com/0IrZPGfxQG

— U.S. FDA (@US_FDA) June 13, 2022

“Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” Kendall Marcus, director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research, said in a statement. “Today’s approval will help fulfill a significant unmet need for patients.”

Olumiant was first approved in 2018 to treat adults with moderate to severe rheumatoid arthritis. Last month, it was also approved for the treatment of COVID-19 in hospitalized adults who need supplemental oxygen or who are on a ventilator.

The treatment works by blocking specific enzymes, which interferes with the pathway that leads to inflammation and can help calm down an overactive immune system. Olumiant isn’t recommended for use in combination with other immunosuppressant drugs and common side effects can include upper respiratory tract infections, headache, acne, high cholesterol and some other medical conditions.

“There is a significant unmet medical need for people with alopecia areata given there has never been an FDA-approved systemic medicine,” Patrik Jonsson, Lilly’s senior vice president for immunology, said in a statement. “Our mission is to make life better for people living with debilitating immune-mediated diseases. Olumiant’s approval is a historic moment.”

Alopecia was the subject of national attention back in March, when actor Will Smith slapped Chris Rock on stage at the Oscars after the comedian made a joke about his wife Jada Pinkett Smith’s short hair. The actress and host of “Red Table Talk” has been vocal about her struggle with alopecia, during one 2018 episode revealing that it was “terrifying” when the hair loss first started.

“I was in the shower one day and then just handfuls of hair just in my hands,” Pinkett Smith said at the time. “It was one of those times in my life that I was literally shaking with fear.”

Sign up for the Coins2Day Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Authors
By Madison Muller
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.